Critical Path Institute (C-Path)

Wishing our amazing LinkedIn community a fun and safe 4th! 🎆 #CPath #collaboration #drugdevelopment #datasharing #globalhealth

🎗 July is Sarcoma Awareness Month and the C-Path team is proudly wearing their Lane United FC jerseys to support tonight's game in Eugene, Oregon. We stand united with the team and community to raise awareness for sarcoma and show our support for all those affected by this rare cancer. Join us in spreading awareness and cheering on Lane United FC! Let's make a difference together. For more on John R. Galas inspiring journey and how he’s battling sarcoma with the same determination he brings to soccer, read his impact story here: https://lnkd.in/gGWUuhEa Lane United FC xCures CURE ID hummel Anna Galas Kristen Swingle Mark Drew Claire Bassetti Alexander Diegel Dave Galas Kristopher Michael Wood #CPath #LaneUnitedFC #UnitedAgainstCancer #xCures #hummel #CDRC #ImpactStory #Sarcoma #SarcomaAwareness #DrugDevelopment #DrugRepurposing #DataSharing #GlobalHealth

Upcoming Webinar: The Influential Role of Patient Advocacy Groups in Registry Data Efforts Join us on Thursday, July 18, at 12 p.m. ET for an insightful webinar hosted by C-Path's Mitochondrial and Inherited Metabolic Diseases Task Force. Discover how patient advocacy groups are pivotal in driving registry data efforts for mitochondrial and inherited metabolic diseases, ensuring that patient experiences and outcomes are central to research and regulatory decision-making. Our presenters include: Sophia Zilber 🌺Board Member and Patient Registry Director, Cure Mito Foundation. Sophia brings over 20 years of experience in drug development and clinical data analysis, leading the global Leigh syndrome patient registry at the Cure Mito Foundation. Elizabeth Reynolds, Co-Founder and Executive Director, The Champ Foundation. Dr. Reynolds has spearheaded over $2 million in research grants for Single Large-scale mtDNA Deletion Syndromes and co-leads a multi-site Natural History Study and patient-registry. Amanda Klein, Executive Director, Critical Path for Lysosomal Diseases and the Alpha-1 Antitrypsin Deficiency Consortia at C-Path. Dr. Klein leads initiatives to accelerate drug development for mitochondrial and inherited metabolic diseases and is a key figure in the RDCA-DAP initiative. Don’t miss this opportunity to learn from experts about the crucial role of patient advocacy in advancing research and healthcare outcomes. 🔗 Register now to secure your spot: https://lnkd.in/eNExmF9R #CPath #PatientAdvocacy #MitochondrialDiseases #Webinar #HealthcareInnovation #DrugDevelopment #collaboration #datasharing

REGISTER NOW 📆 C-Path's Predictive Safety Testing Consortium is delighted to announce its second public workshop on evidentiary considerations for regulatory assessment and qualification of complex in vitro models - CIVMs. Health authorities, academia professionals, model developers, and representatives from the pharmaceutical industry are encouraged to participate in this workshop. It offers a valuable platform for attendees to engage in discussions and deliberations regarding the evidentiary considerations essential for regulatory assessment and qualification of CIVMs. Through collaborative efforts, attendees will strive to reach a consensus on the standards and features necessary to enhance the performance of CIVMs as a reliable tool for drug development and regulatory assessment. The meeting agenda features sessions led by key opinion leaders, who will address general considerations for qualification. Additionally, interactive breakout sessions will concentrate on various organ systems and disease models. During these breakouts, participants will actively engage in discussions and deliberations to explore the evidentiary considerations crucial for regulatory assessment and qualification of complex in vitro models. Join us September 26 - 27, 2024 in Bethesda, Maryland. Register now: https://lnkd.in/gKXn8R4e. #CPath #PSTC #CIVM #workshop #drugdevelopment #datasharing #regulatoryscience #collaboration #globalhealth

🔍 How can #AI and #ML approaches help identify and appraise registries and relevant data? Join us for an insightful webinar on Tuesday, July 9 at 3 PM CET to find out! We are honored to host distinguished speakers and regulatory experts: ▶ Peter Mol, More-EUROPA ▶ Luis Correia Pinheiro, European Medicines Agency ▶ Nicolas Löffler-Perez , PhD, Swissmedic ▶ Ghinwa Hayek, Quinten Health ▶ Billy AMZAL, Quinten Health Don't miss this opportunity to learn from the best in the field! 👉 Secure your spot now: https://lnkd.in/e2MeSqjU #CPath #CPathEurope #drugdevelopment #datasharing #collaboration #HealthData #Healthcare #MachineLearning #RegulatoryScience Klaus Romero Cécile Ollivier Eva Fernandez Kimberly Ward Barowicz Sieta de vries Lysbeth Bakker Carla Torre Bruno Sepodes

We are thrilled to announce the collaboration between the C-Path’s International Neonatal Consortium and the National Association of Neonatal Nurses (NANN) in the published manuscript: "Open Access to Neonatal Drug Development Education Modules." This article, authored by Mary Short and published in Neonatology Today, details our partnership to provide foundational knowledge on innovative, regulated medicine development for neonates. 🔗 Read the full article here: https://lnkd.in/g9Qexwsh Access the eduction modules, here: https://lnkd.in/g_xQPt-D Joseph Hedrick Kanwaljit Singh, MD, MPH, MBA Gina Smith Christine Barry Molly Anderson #CPath #INC #NANN #Pediatrics #neonatal #education #drugdevelopment #datasharing #globalhealth #collaboration

🌟July is Sarcoma Awareness Month | Impact Story Highlight: United Against Cancer: John Galas’ Impact on Sarcoma and Soccer 🌟 John R. Galas has spent most of his life around soccer. At an early age, he developed a deep passion for the sport and embraced the competitive spirit inherent in it. This mindset that proved invaluable when he faced his toughest opponent yet: cancer. Diagnosed with a rare sarcoma in October 2023, John confronted this challenge with the same determination he displayed as both a player and coach. Despite the uncertainty, he remained focused on one outcome: victory. With unwavering support from family and friends, and a relentless fighting spirit, he embarked on a courageous battle against cancer. “I’ve got one option and that’s to win, however long that takes, no matter how uncomfortable it might be. I just had a mindset that I was going to win, and this was one speed bump along the way,” John said. “The mentality was to fight and to stay positive, much like I coach my teams.” Read the full impact story and be inspired by John’s journey: https://lnkd.in/gGWUuhEa Lane United FC xCures CURE ID hummel Anna Galas Claire Bassetti Alexander Diegel Dave Galas #CPath #LaneUnitedFC #UnitedAgainstCancer #xCures #hummel #CDRC #ImpactStory #Sarcoma #SarcomaAwareness #DrugDevelopment #DrugRepurposing #DataSharing #GlobalHealth

C-Path's Nicholas King and Graham Marsh are in Milan this week for the EUROoCS Annual Meeting 2024. This premier scientific meeting brings together global experts in organs-on-chip and microphysiological systems. #EUROoCS2024 will showcase cutting-edge advancements and foster discussions on various topics, including (multi)-organ and disease models, organoids-on-chip, PK/PD modeling, technology platforms, read-out assays, standardization, qualification, and toxicity. PSTC collaborates with pharmaceutical companies and regulatory bodies like the FDA, European Medicines Agency and PMDA to develop and qualify improved clinical safety biomarkers for drug development. 🔗 Learn more about EUROoCS2024: https://lnkd.in/dcEuhTc 🔗 More about PSTC: https://c-path.org/pstc #CPath #EUROoCS #PSTC #DrugSafety #DrugDevelopment #DataSharing #Collaboration #GlobalHealth

Check out C-Path's latest article in the SOATT Newsletter titled "The Critical Path Institute: International Neonatal Consortium Cell and Gene Therapy Initiative" by Christine Barry, MPH, Gina Smith, MPH, RN, Kanwaljit Singh, MD, MPH, MBA, and Klaus Romero. Cell and gene therapies are revolutionizing treatment for hereditary, congenital, and genetic abnormalities. This article dives into the ethical, scientific, and operational challenges of developing these groundbreaking therapies, particularly for neonates and infants. Discover how these innovative approaches can make a lasting positive impact on lives from the earliest stages. Shared with permission from the AAP Section on Advances in Therapeutics and Technology For more information on C-Path's International Neonatal Consortium, visit: https://lnkd.in/gC-5QY-T #CPath #INC #CellAndGeneTherapy #NeonatalHealth #PediatricResearch #RegenerativeMedicine #SOATT #HealthcareInnovation #DrugDevelopment #datasharing

Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/ge-FMrxv For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience